@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 2/ #TumorBoardTuesday
Thurs Case🎀

Take🏠messages :
PIK3CA mutations in ER+ #mBC
✅PIK3CA mut are common- 20-30% of all #BreastCancer & 40%+ of ER+ #mBC
✅PIK3CAm are present in founder clones!

📚We captured as much of the discussion as we could:
Pt 1 twitter.com/i/events/15719…
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 3/5 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages (Part 2):
✅Alpelisib is a PIK3CA inhib= 5.3 mo ⬆️in PFS
✅Side effect mgmt is key- esp. 💩diarrhea,
🍦hyperglycemia
✅Personalized medicine needs personalized side effect mgmt

Part 2 of our convo twitter.com/i/events/15729…
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 4/5 #TumorBoardTuesday
📷 TBT in an image: Take a look at how PIK3CA inhibitors can be clinically deployed, key side effects to watch out for, and the data that supports their use.

👀Look for more developments in this space and even more, highly specific inhibitors to come. Image
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD @esinghimd @EricaMarieRomn1 @ca_pik3 @RenoHemonc @OncBrothers @marina_sharifi 5/5 #TumorBoardTuesday
Thursday Case🎀

Thank you to @maryamlustberg & @JasmineSukumar for an excellent #TBT- PIK3CA= new 2L option, but with side effects that need proactive mgmt!

➡️Join us on 𝗠𝗢𝗡𝗗𝗔𝗬 10/03/22 at 8PM ET: @n8pennell discusses Dato-DXd #NSCLC 3L 🫁

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Johnathan Ebben MD, PhD

Johnathan Ebben MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @JohnEbbenMDPhD

Sep 9
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation 2/3 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:

✅3 agents (pembro, atezo, cempilimab) 👍🏽PD-L1 TPS >50% in 1L
– No head to head ICI comparisons
✅OS BETTER w IO alone vs chemo
✅💰tox huge problem!
📚We captured the convo in this moment:
twitter.com/i/events/15675…
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation 2.5/3 #TumorBoardTuesday
Thurs Case🎀

Key factors to choose ICI (in absence of head to head trials):
- Pt experiences/preferences
- Dosing schedule
- $$$ toxicity

The good news: across 3 separate agents (pembrolizumab, atezolizumab, cemiplimab) OS is BETTER w IO alone vs chemo Image
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation @esinghimd @jacobadashek @KinhHoangMD @RenoHemonc @tanyawildes @OncBrothers 3/3
Thurs Case🎀

Thanks for joining us for #TumorBoardTuesday!

Some scheduling notes:
@jane_meisel’s #BRCA case is rescheduled for 12.20.22

➡️Please be sure to join us on 09/20/22 when @maryam_lustberg @JasmineSukumar present a case focused on PIK3CA inhibition in #mBC 😀
Read 8 tweets
Sep 2
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD 1/3 #TumorBoardTuesday
Case🎀

Take🏠messages:
In unresectable stage III #NSCLC:
✅ChemoXRT -> IO is SOC
✅STK11 = ⬇️response to IO, but IO still👍🏼after chemoXRT
✅New IO combos- COAST trial ongoing

📚We captured @HosseinBorghaei’s discussion:
twitter.com/i/events/15648…
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD 2/3 #TumorBoardTuesday
Case🎀

📷 TBT in an image:

We summed it up in a graphic- check out management of unresectable stage III #NSCLC, with updated data from PACIFIC, + exciting data from ongoing COAST trial (evaluating anti-CD73 w ICI; anti-NKG2A w ICI).
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD @esinghimd @LaurenBzak @jacobadashek @VivekSubbiah @BiagioMd @FSkoulidis 3/3 #TumorBoardTuesday
Case🎀

Next: we’ll delve into choosing a checkpoint inhibitor (which one??) in the 1L setting in PD-L1 high #NSCLC, with experts @NarjustFlorezMD & @ShrutiPatelMD taking us through their clinical approach.

Have a great and safe holiday weekend!
Read 6 tweets
Aug 19
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer 2/3 #TumorBoardTuesday
Thurs Case🎀

Take🏠:
✅HER2 LOW= IHC1+ OR IHC2+ w - ISH (67% HR+!)
✅T-DXd= after 1L chemo in HER2 low
✅Careful monitoring for ILD!

📚We captured @hoperugo & @LauraHuppert’s discussion in below:

twitter.com/i/events/15588…

twitter.com/i/events/15601…
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer @LauraHuppert 2.75/3 #TumorBoardTuesday

Check out this graphic outlining the key role for ADCs in the tx of HER2 low #MBC after prior 1L chemo and endocrine therapy.

Hoping for even more changes in the near future w
DB-06! Image
Read 7 tweets
Aug 12
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek 2/5 #TumorBoardTuesday
Thursday Case🎀

Take🏠:

✅High risk feat= consider adj tx
✅Sunitinib= FDA ☑️; can be hard to tolerate
✅Pembro= FDA ☑️ w DFS benefit
✅irAE mgmt - gr3+= steroids

📚We captured @brian_rini’s discussion in this moment: twitter.com/i/events/15552…
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek 3/5 #TumorBoardTuesday
Thursday Case🎀

📷 TBT in an image: 👀out a clinical algorithm 📊for adj therapy in #RCC.

Some pearls re: irAE mgmt & addtl info to help choose a patient appropriate adjuvant regimen! Image
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek @esinghimd @PaulCrispenMD @apolo_andrea @AmandaNizamMD 4/5 Thurs Case 🎀
#PostTest Q2️⃣ #CME #TumorBoardTuesday
FREE CME🔗 integrityce.com/tbt
CME eval🔗 integrityce.com/TBTeval

Now that you’ve reviewed- try your hand at #CME:

🤨Which strategy would you use for a pt receiving pembrolizumab experiencing #IBD colitis (grade 3)?
Read 10 tweets
Aug 5
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD 2/5 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages

✅BRCAm= 10-20% of TNBC!
✅PD-L1 CPS>10= PFS & OS benefit w/ IO in mTNBC
✅PARPi= PFS benefit
✅Biomarkers, side effects, pt pref key

📚We captured much of @dradityabardia @ariellemedford’s discussion: twitter.com/i/events/15548…
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD 3/5 #TumorBoardTuesday
Thursday Case🎀

How do you choose IO vs PARPi in #TNBC w #BRCA mutation? Check out the summary and algorithm below!
Important to know there are more 2L options as well, including sacituzumab-gov & other ADCs. New trials evaluating IO+ PARPi–stay tuned!
Read 11 tweets
Jul 22
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 1/8 #TumorBoardTuesday

🔬🧬Discussion on 1L treatment for BRCA+ #MBC led by @PTarantinoMD @CaterinaSpo #BreastCancer

➡️Here’s the week's Thursday Case 🎀

👉Don’t forget your🆓 #CME credit by answering 1 quick❓
CME🔗: integrityce.com/tbt
CME eval🔗: integrityce.com/tbteval
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 2/8 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages for germline #BRCAm & 2L tx in #BreastCancer
✅BRCAm fairly common - 10-20% of #TNBC
✅PARPi approved in met, BRCAm dz
✅Fast responses, with ORR > chemo

📚Much of @PTarantinoMD @CaterinaSpo’s chat👇🏽
twitter.com/i/events/15487…
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 2.33/8 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages (continued):

✅Toxicities for 🤢, myelosuppression- managed w ⬇️ reduction, tx holiday
‼️(remember 3-5% risk of MDS/AML)‼️
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(